Jfs Wealth Advisors Lowers stake in Iradimed Corp (IRMD)

Iradimed Corp (IRMD) : Jfs Wealth Advisors reduced its stake in Iradimed Corp by 7.32% during the most recent quarter end. The investment management company now holds a total of 190,000 shares of Iradimed Corp which is valued at $3,661,300 after selling 15,000 shares in Iradimed Corp , the firm said in a disclosure report filed with the SEC on Jul 25, 2016.Iradimed Corp makes up approximately 0.99% of Jfs Wealth Advisors’s portfolio.

Other Hedge Funds, Including , Skylands Capital sold out all of its stake in IRMD during the most recent quarter. The investment firm sold 33,246 shares of IRMD which is valued $640,650.Conestoga Capital Advisors reduced its stake in IRMD by selling 33,175 shares or 10.33% in the most recent quarter. The Hedge Fund company now holds 287,835 shares of IRMD which is valued at $5,699,133. Iradimed Corp makes up approx 0.41% of Conestoga Capital Advisors’s portfolio. Magee Thomson Investment Partners sold out all of its stake in IRMD during the most recent quarter. The investment firm sold 118 shares of IRMD which is valued $2,336.Creative Planning reduced its stake in IRMD by selling 90 shares or 3.44% in the most recent quarter. The Hedge Fund company now holds 2,527 shares of IRMD which is valued at $51,576.Bnp Paribas Arbitrage Sa boosted its stake in IRMD in the latest quarter, The investment management firm added 33 additional shares and now holds a total of 160 shares of Iradimed Corp which is valued at $3,541.

Iradimed Corp opened for trading at $18.9 and hit $20.17 on the upside on Friday, eventually ending the session at $19.36, with a gain of 4.31% or 0.8 points. The heightened volatility saw the trading volume jump to 1,42,978 shares. Company has a market cap of $211 M.

On the company’s financial health, Iradimed Corp reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.21. The company had revenue of $9.90 million for the quarter, compared to analysts expectations of $9.61 million. The company’s revenue was up 30.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.16 EPS.

IRADIMED CORPORATION (IRADIMED) develops manufactures markets and distributes Magnetic Resonance Imaging (MRI) compatible products and provides non-magnetic intravenous (IV) infusion pump systems. The Company’s electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency (RF) noise create interference and are dangerous to operate in the presence of the magnet which drives an MRI. The Company’s MRidium 3860+ MRI compatible IV infusion pump system consists of non-ferrous parts ceramic ultrasonic motors non-magnetic mobile stands and other special features to deliver anesthesia and other IV fluids during various MRI procedures. As of December 31 2014 the Company had approximately 2300 MRI compatible IV infusion pump systems installed globally. Each system consists of an MRidium MRI compatible IV infusion pump mobile stand and disposable IV tubing sets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Iradimed Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Iradimed Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.